HOME PAGE >>Order > Products > Food Supplements > All Products > All Products > Food Supplements > React® HyPerVital
React® HyPerVital
Product Code: 0006
Barcode: 5200138430006
Multivitamin
React® HyPerVital
- Reinforce the normal function of the immune system: folic acid, b-carotene, vitamins B6, B12 and D,
- Protect cells from oxidative stress: folic acid5, b-carotene, glutathione6, acetyl coenzyme Q107, SOD8
- Support normal steroid hormone synthesis and metabolism as well as hormonal activity regulation: Vit Β5 and Vit Β6, respectively.
Product features
- Vitamins, minerals, trace elements and stem cells!
- 6 ingredients to fortify the immune system.
- 6 antioxidant ingredients in a single dose.
- High-concentration boosting ingredients.
- Convenient drinkable sachet format.
- Excellent taste.
- Developed and manufactured in Greece.
Benefits
B-carotene and vitamin E: dietary intake of b-carotene
and vitamin E is inversely proportional to the risk of
developing cervical cancer.9
- Folic acid: its low levels are associated with an increased risk of cervical cancer.5
- Acetyl Coenzyme Q10: plasma concentrations of coenzyme Q10 and vitamin E are inversely proportional to epithelial lesions.6
- Glutathione: major antioxidant for somatic and germ cells.7
Each pack contains 30 drinkable sachets promising great taste
GREEK PRODUCT
National Organization for Medicines (EOF) Notification Number: 114569/29-9-2025
The notification number assigned by EOF is not equivalent to a marketing authorization by EOF
_
References1. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006; 367(9509): 489-98.
2. Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, Prendiville W, Paraskevaidis E. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008; 337: a1284.
3. Founta C, Arbyn M, Valasoulis G, Kyrgiou M, Tsili A, Martin-Hirsch P, Dalkalitsis N, Karakitsos P, Kassanos D, Prendiville W, Loufopoulos A, Paraskevaidis E. Proportion of excision and cervical healing after large loop excision of the transformation zone for cervical intraepithelial neoplasia. BJOG 2010; 117(12): 1468-74.
4. Kyrgiou M, Mitra A, Arbyn M, Stasinou SM, Martin-Hirsch P, Bennett P, Paraskevaidis E. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. BMJ 2014; 349: g6192.
5. Kyrgiou M, Mitra A, Arbyn M, Paraskevaidi M, Athanasiou A, Martin-Hirsch PP, Bennett P, Paraskevaidis E. Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia. Cochrane Database Syst Rev 2015; 2015(9): CD008478.
6. Kyrgiou M, Valasoulis G, Stasinou SM, Founta C, Athanasiou A, Bennett P, Paraskevadis E. Proportion of cervical excision for cervical intraepithelial neoplasia as a predictor of pregnancy outcomes. Int J Gynaecol Obstet 2015; 128(2): 141-7.
7. Kyrgiou M, Athanasiou A, Paraskevaidi M, Mitra A, Kalliala I, Martin-Hirsch P, Arbyn M, Bennett P, Paraskevaidis E. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ 2016; 354: i3633.
8. Kyrgiou M, Mitra A, Paraskevaidis E. Fertility and Early Pregnancy Outcomes Following Conservative Treatment for Cervical Intraepithelial Neoplasia and Early Cervical Cancer. JAMA Oncol 2016; 2(11): 1496-8.
9. Kyrgiou M, Athanasiou A, Kalliala IEJ, Paraskevaidi M, Mitra A, Martin-Hirsch PP, Arbyn M, Bennett P, Paraskevaidis E. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database Syst Rev 2017; 11(11): CD012847.
10. Paraskevaidis E, Athanasiou A, Paraskevaidi M, Bilirakis E, Galazios G, Kontomanolis E, Dinas K, Loufopoulos A, Nasioutziki M, Kalogiannidis I, Athanasiadis A, Papanikolaou A, Vatopoulou A, Grimbizis G, Tsolakidis D, Daponte A, Valasoulis G, Gritzeli S, Michail G, Adonakis G, Paschopoulos M, Tsonis O, Anaforidou ME, Batistatou A, Kyrgiou M, HeCPA Group. Cervical Pathology Following HPV Vaccination in Greece: A 10-year HeCPA Observational Cohort Study. In Vivo 2020; 34(3): 1445-9.
11. Athanasiou A, Veroniki AA, Efthimiou O, Kalliala I, Naci H, Bowden S, Paraskevaidi M, Arbyn M, Lyons D, Martin-Hirsch P, Bennett P, Paraskevaidis E, Salanti G, Kyrgiou M. Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and
network meta-analysis. Lancet Oncol 2022; 23(8): 1097-108.
12.Paraskevaidis E, Athanasiou A, Ellis LB, Bowden SJ, Kyrgiou M. Individualised care for cervical precancer. BMJ 2025; 388: r7.
|
Συστατικά |
Ποσότητα ανά 10ml φακελίσκο |
Συνιστώμενη Ημερήσια ∆όση |
|
Apple root extract |
100μg | ** |
|
B-Carotene 10% |
100mg | ** |
|
Coenzyme Q10 |
40mg |
** |
| Cooper (as gluconate) | 140μg | 45,6%* |
| Folic Acid | 800μg | 400%* |
| Kelp | 20mg | ** |
| L-Glutathione | 300mg | ** |
| Marigold Extract | 100μg | ** |
| Pine bark extract | 600μg | ** |
| Black pepper extract | 50μg | ** |
| Rhodiola rosea extract | 100μg | ** |
| Rose Extract | 1μg | ** |
| Astaxanthin | 3mg | ** |
| SOD | 1μg | ** |
| Selenium (as sodium) | 25.08μg | 45.6%* |
| Vitamin B1 | 1.78mg | 162%* |
| Vitamin B5 | 5.98mg | 100%* |
| Vitamin B6 | 2.22mg | 156%* |
| Vitamin B12 | 2.76μg | 110%* |
| Vitamin D3 | 2000IU | 1000% |
| Vitamin E succianate | 24.3mg | 202.5% |
| Zinc (as gluconate) | 7.9mg | 79% |
| Vitamin K2 (menaquinone-7) | 200μg | 267%* |
Other ingredients: Xanthan gum, Sodium Hydroxide, Potassium Sorbate, Sodium Benzoate, Sucralose, Banana Flavor.
Instructions for Use:
Storage instructions:
For allergens see ingredients.
